

Alvaro Cobo-Calvo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3628175/publications.pdf>

Version: 2024-02-01

36
papers

1,953
citations

393982

19
h-index

315357

38
g-index

40
all docs

40
docs citations

40
times ranked

1792
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. <i>Neurology</i> , 2018, 90, e1858-e1869.	1.5	401
2	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	4.9	261
3	Neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e225.	3.1	134
4	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41.	2.8	123
5	MOG antibody-related disorders: common features and uncommon presentations. <i>Journal of Neurology</i> , 2017, 264, 1945-1955.	1.8	119
6	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	3.1	115
7	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021, 28, 3384-3395.	1.7	111
8	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	0.9	110
9	Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. <i>Multiple Sclerosis Journal</i> , 2016, 22, 312-319.	1.4	79
10	Cranial nerve involvement in patients with MOG antibody-associated disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e543.	3.1	53
11	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019, 266, 806-815.	1.8	47
12	Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 299, 112-117.	1.1	43
13	Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. <i>Current Opinion in Neurology</i> , 2019, 32, 459-466.	1.8	38
14	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.	1.4	37
15	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021, 97, e1641-e1652.	1.5	35
16	Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 741-752.	1.4	26
17	The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab. <i>Frontiers in Immunology</i> , 2019, 10, 2686.	2.2	25
18	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. <i>Journal of Neuroradiology</i> , 2021, 48, 28-36.	0.6	24

#	ARTICLE	IF	CITATIONS
19	Etiologic Spectrum and Prognosis of Longitudinally Extensive Transverse Myelopathies. <i>European Neurology</i> , 2014, 72, 86-94.	0.6	22
20	Paraneoplastic neuromyelitis optica and ovarian teratoma: A case series. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 97-100.	0.9	19
21	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, e1143.	3.1	17
22	Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody-associated acute demyelinating syndromes. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 1075-1081.	1.1	13
23	Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis. <i>European Neurology</i> , 2015, 73, 220-229.	0.6	12
24	The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. <i>Brain</i> , 2022, 145, 3931-3942.	3.7	12
25	Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability. <i>PLoS ONE</i> , 2020, 15, e0238301.	1.1	11
26	Baseline MxA mRNA Expression Predicts Interferon Beta Response in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2014, 9, e112758.	1.1	11
27	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1138-1145.	1.4	11
28	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 950-957.	1.4	7
29	Optic Neuritis in the Setting of NMDA Receptor Encephalitis. <i>Journal of Neuro-Ophthalmology</i> , 2014, 34, 316-319.	0.4	6
30	Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis. <i>Clinical Immunology</i> , 2016, 171, 18-24.	1.4	6
31	MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity “No. <i>Multiple Sclerosis Journal</i> , 2020, 26, 274-276.	1.4	6
32	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. <i>Journal of Neurology</i> , 2022, 269, 1764-1772.	1.8	5
33	MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2016, 291, 73-77.	1.1	3
34	Myelin oligodendrocyte glycoprotein antibody associated disease: about the importance of diagnostic assays and selection of the target population in retrospective studies. <i>European Journal of Neurology</i> , 2019, 26, e58-e59.	1.7	3
35	Feasibility and Effects of Structured Physical Exercise Interventions in Adults with Relapsing-Remitting Multiple Sclerosis: A Pilot Study. <i>Journal of Sports Science and Medicine</i> , 2018, 17, 426-436.	0.7	3
36	Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay. <i>Acta Neurologica Belgica</i> , 2022, 122, 823-825.	0.5	3